Overview The EMPA-FIT Study Status: RECRUITING Trial end date: 2025-12-31 Target enrollment: Participant gender: Summary This multicenter, open-label, prospective study randomized 46 drug-nave adults with T2D (HbA1c 6.5%-10.0%) to receive empagliflozin (10 mg/day) or metformin (1,000 mg/day) for 12 weeks.Phase: PHASE4 Details Lead Sponsor: Seoul National University Bundang HospitalTreatments: empagliflozinMetformin